Table of Contents
<< Previous Issue | Jun 2014 (Vol: 2014, Issue: 6) | Next Issue >> |
- Section: Licensing
-
Janssen Strengthens Prostate Cancer Pipeline with Aduro BioTech Collaboration
- Section: Mergers & Acquisitions
-
Merck & Co. Divests Nine Ophthalmology Brands to Japan’s Santen Pharmaceutical
-
Lundbeck Adds to Neurology Portfolio with Chelsea Therapeutics Acquisition
-
Abbott Targets Growth in Emerging Markets with CFR Pharmaceuticals Acquisition
-
Hikma Builds Presence in US Injectables Market via Boehringer Ingelheim Asset Purchase
- Section: Research & Development
-
Regeneron Looks to Avalanche’s Ocular BioFactory™ for Potential Eylea® Successor
-
BMS Continues Immuno-Oncology Push via Deals with CytomX and Incyte